Robert W. Baird reaffirmed their buy rating on shares of Natera, Inc. (NASDAQ:NTRA) in a report issued on Tuesday, October 24th.
A number of other equities analysts also recently issued reports on NTRA. Zacks Investment Research upgraded Natera from a sell rating to a buy rating and set a $9.25 price objective for the company in a report on Thursday, August 10th. Cowen and Company restated a buy rating and set a $14.00 price target on shares of Natera in a report on Friday, September 1st. BidaskClub upgraded Natera from a sell rating to a hold rating in a report on Wednesday, August 23rd. Morgan Stanley dropped their price objective on Natera from $18.00 to $13.00 and set an overweight rating on the stock in a research report on Monday, August 7th. Finally, ValuEngine raised Natera from a strong sell rating to a sell rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Natera presently has a consensus rating of Hold and a consensus price target of $15.25.
Shares of Natera (NASDAQ:NTRA) opened at $9.19 on Tuesday. Natera has a one year low of $7.35 and a one year high of $14.76.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $56.66 million during the quarter, compared to analyst estimates of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 167.13%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) EPS. analysts expect that Natera will post -2.12 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/nateras-ntra-buy-rating-reiterated-at-robert-w-baird.html.
In related news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the completion of the transaction, the insider now owns 533,208 shares in the company, valued at approximately $6,686,428.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.57% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the business. Virtu KCG Holdings LLC purchased a new stake in shares of Natera in the 2nd quarter worth $126,000. American International Group Inc. raised its position in shares of Natera by 7.1% in the 1st quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after acquiring an additional 1,068 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Natera by 1.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after acquiring an additional 194 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Natera in the 2nd quarter worth $151,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Natera by 45.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after acquiring an additional 5,417 shares in the last quarter. Institutional investors and hedge funds own 59.89% of the company’s stock.
Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.